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s u m m a r y
Objective: We aimed to test whether a national Enhanced Recovery After Surgery (ERAS) Programme in
total knee replacement (TKR) had an impact on patient outcomes.
Design: Natural-experiment (April 2008eDecember 2016). Interrupted time-series regression assessed
impact on trends before-during-after ERAS implementation.
Setting: Primary operations from the UK National Joint Registry (NJR) were linked with Hospital Episode
Statistics (HES) data which contains inpatient episodes undertaken in National Health Service (NHS)
trusts in England, and Patient Reported Outcome Measures (PROMs).
Participants: Patients undergoing primary planned TKR aged 18 years.
Intervention: ERAS implementation (April 2009eMarch 2011).
Outcomes: Regression coefﬁcients of monthly means of Length of stay (LOS), bed day costs, change in
Oxford knee scores (OKS) 6-months after surgery, complications (at 6 months), and rates of revision
surgeries (at 5 years).
Results: 486,579 primary TKRs were identiﬁed. Overall LOS and bed-day costs decreased from 5.8 days to
3.7 and from £7607 to £5276, from April 2008 to December 2016. Oxford knee score (OKS) change
improved from 15.1 points in April 2008 to 17.1 points in December 2016. Complications decreased from
4.1 % in April 2008 to 1.7 % in March 2016. 5-year revision rates remained stable at 4.8 per 1000 implants
years in April 2008 and December 2011. After ERAS, declining trends in LOS and bed costs slowed down;
OKS improved, complications remained stable, and revisions slightly increased.
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Conclusions: Different secular trends in outcomes for patients having TKR have been observed over the
last decade. Although patient outcomes are better than a decade ago ERAS did not improve them at
national level.
© 2019 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Introduction
Between April 2009 and March 2011 the UK Department of
Health implemented an Enhanced Recovery After Surgery (ERAS)
Partnership Programme1 to improve recovery in colorectal,
musculoskeletal, gynaecology and urology surgical pathways. The
ﬁrst year of the programme focussed on learning best practice from
pioneer units of ERAS practice in the National Health Service (NHS).
It collected information about principles of enhanced recovery,
clinical elements of the patient pathway, metrics and success fac-
tors. It established a website to share information and resources,
generated a ﬁnancial and equality impact evaluation, published an
implementation guide, and developed an online reporting tool to
support implementation. A lead for enhanced recovery was named
in each local health authority to prepare for a programme of spread
and adoption across the NHS during the ERAS implementation in
the second year of the programme.
Hip and knee replacement were the focus of ERAS in musculo-
skeletal care. ERAS is a complex intervention2,3 that focuses on
several areas of care across patients' pathways through surgery:
pre-operatively (for the patient to be in the best possible condition
for surgery); peri-operatively4 (the patient has the best possible
management during and after their operation); post-operatively
(the patient experiences the best rehabilitation). The intervention
includes provision of information before and after surgery,
comprising elements such as making changes around the home,
strengthening exercises, and changes to nutrition. For patients in
whom it is suitable, ERAS aims to enable earlier return home from
hospital with tailored discharge. A greater number of frail older
people with complex co-morbid conditions now receive hip/knee
replacement surgery. The new ERAS pathways' could speciﬁcally
beneﬁt these patient groups5.
There is limited evidence concerning the effectiveness of ERAS
programmes6, particularly when applied nationwide across a
healthcare system with variation in the way hospitals organise
enhanced recovery services and it is unclear which way is best.
Length of stay (LOS) has been declining prior to the intervention,
and we hypothesised that after the implementation of ERAS, this
downward secular trend would decline faster. For the outcomes of
complications, revision, pain and function, we did not have a spe-
ciﬁc a-prior hypothesis as it is unclear what impact ERAS would
have on these outcomes. Our aim is to see if introduction of the
ERAS programme for knee replacement has led to improved patient
outcomes: less knee pain and better knee function, fewer surgical
complications, fewer revision operations and reduced LOS.
Methods
Study design
We used a natural experimental study design19. We evaluated
the impact of ERAS on trends before (April 2008eMarch 2009),
during (April 2009eMarch 2011) and after the intervention (April
2011eDecember 2016)20,21 (Supplementary Fig. S1). The timing of
implementation of ERAS varied by trust and was assumed to span
the 2 years of the implementation period (April 2009eMarch 2011).
Participants and inclusion criteria
We included only patients receiving elective surgery (Fig. 1)
between 1 April 2008, and 31 December 2016. We excluded pa-
tients without a concordant date of surgery between the UK Na-
tional Joint Registry (NJR) and Hospital Episode Statistics (HES)
databases.
Further exclusions were made speciﬁc to the outcome being
analysed. For LOS we excluded patients staying more than 15 days
at hospital. Patients with missing data for LOS were excluded. We
excluded patients without information on baseline and/or 6-
months follow-up for the analysis of change in Oxford knee
scores (OKS). However, we used all patients in a sensitivity analysis
after imputing missing values. For complications we excluded pa-
tients with surgery after June 2016 to guarantee all patients had at
least 6-months of follow up. For revision at 5 years we excluded
patients receiving surgery after 2011 to ensure all patients had at
least 5-years follow up.
Data source
We used the NJR to obtain data on primary knee replacements.
NJR contains data on knee replacement surgeries from 149 UK NHS
trusts. NJR includes two million patients since 2003, covering 96%
and 90% of primary knee replacements and knee revisions,
respectively7.
Data linkages
Primary operations were linked with HES data which contains
records of all inpatient episodes undertaken in NHS trusts in En-
gland (125 million each year). Knee replacements were linked to
Patient Reported Outcome Measures (PROMs). A cohort of patients
undergoing primary total knee replacement (TKR) in England, UK,
was retrieved for the period April 2008eDecember 2016.
Outcome measures
We evaluated trends for LOS at hospital for patients undergoing
primary TKR. LOS was calculated as the number of days between
hospital admission and discharge date. Time points for the trends
were monthly mean LOS. We estimated the inpatient cost relating
to the index episode using NHS reference costs from 2015/168. We
estimated the mean cost per bed day based on the healthcare
resource use (HRG) for each patient and their LOS (Appendix 1).
Monthly mean bed-day costs were the unit of analysis for costs
trends.
We assessed absolute change in OKS. Patients complete the
same questionnaire about their knee pain and function before and 6
months after surgery9. Each question is scored between 0 (worse
symptoms) and 4 (least symptoms). Scores from these 12 questions
are added getting a total score spanning from 0 (worst possible)
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and 48 (best possible score). We calculated the absolute difference
(change) between baseline and 6-month follow-up scores. Higher
positive values for OKS change measure represented greater
improvement. OKS trends were obtained by calculating the
monthly mean OKS change scores.
We estimated mean 6-month complication proportions aggre-
gated bymonth.We deﬁned post-operative complications as one or
more events from the following list: stroke (excluding transient
ischaemic attack), respiratory infection, acute myocardial infarc-
tion, pulmonary embolism/deep vein thrombosis, urinary tract
infection, wound disruption, surgical site infection, fracture after
implant, complication of prosthesis, neurovascular injury, acute
renal failure and blood transfusion (Appendixes 2 and 3).
We evaluated the rate of revision at 5 years bymonth of primary
TKR. We included revisions declared to the NJR registry by the
surgeons10 and revisions reported to HES using codes from
Appendix 4. We speciﬁed our analysis time in years reporting the
rate as number of revisions per 1000 implant-years.
Intervention
Nation-wide ERAS implementation was carried out between
April 2009 to March 2011. During the ﬁrst year the programme
focused on identifying best practice, determining clinical elements
of the patient pathway, publishing an implementation guide, sup-
porting early adopters of the programme to better understand key
factors for implementation and sustainability11. During the second
year ERAS supported local health areas for delivering and
commissioning implementation of ERAS.
Potential modiﬁers
Whether trends in LOS and OKS differed by age (18e59, 60e69,
70e79, 80e84, 85 years) and presence of co-morbidities ac-
cording to the Charlson classiﬁcation12 (none vs one or more
comorbidities) (Appendix 5).
Missing data
We used Pearson's c2 statistic to evaluate missingness for OKS
across categories of study period (before, during, and after ERAS),
age and presence of co-morbidities. OKS at baseline and 6 months
was imputed as a sensitivity analysis. We generated a single
imputed dataset using a chained equation across 50 iterations to
reach a stationary distribution.
Statistical analysis
We described the trends by calculating monthly outcomes, be-
ing means (LOS, bed costs, OKS), proportions (complications), rates
(revision), together with their 95% conﬁdence intervals (CI). We
estimated a fractional polynomial over the study period and plotted
the resulting curve.
Fig. 1. Flow diagram on selection of patients.
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We used an interrupted time series approach to estimate
changes in outcomes during and immediately following the inter-
vention period while controlling for baseline levels and trends. We
modelled aggregated data points of each outcome of interest by
month using segmented linear regression13.
Yt¼ b0 þ ðb1*timetÞ þ ðb2*ERAS0Þ þ ðb3*time after ERAS0Þ
þ ðb4*ERASendÞ þ ðb5*time after ERASendÞ þ et
Yt is the mean number of days at hospital in month t for LOS
outcome; mean OKS change in month t for the PROMs outcome;
mean proportion of complications in month t for the 6-month
complications outcome; and mean rate of revisions in month t for
the 5-year revision outcome. “time” is a continuous variable rep-
resenting number of months from the start of observation period at
time t. Each phase of the study has two parameters: baseline level
and trend:
 Pre-intervention period. b0 estimates the baseline level of the
outcome at the beginning of the time series (i.e., April 2008). b1
estimates the trend before Enhanced Recovery After Surgery
(ERAS) implementation (i.e., before April 2009).
 Intervention period. b2 is the change in level immediately
following the intervention (ERAS0 ¼ April 2009). b3 estimates
the change in the trend in the monthly mean (number or rate
depending of outcome) after ERAS started (i.e., ERAS imple-
mentation trend).
 Post-intervention period. b4 is the change in level immediately
following the end of the intervention (ERASend ¼ March 2011).
b5 estimates the change in the trend in the mean monthly
number or rate (depending of outcome) after ERAS ended (i.e.,
ERAS post-implementation trend).
In preliminary analysis we checked the autocorrelationwith the
previous month, 2 months … until the previous 12 months using
Durbin's alternative test14. We estimated linear regression models
with NeweyeWest standard errors15.
All analyses were conducted using Stata version 13.1 (StataCorp,
College Station, Texas). We followed the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE)
guideline16.
Results
Between April 2008 and December 2016 there were 486,579
planned primary TKR (Fig. 1). 57% of patients were women, the
average age was 70 years (SD ± 9 years). Mean body mass index
(BMI) pointed to a nutritional status of obesity class I 31.0 kg/m2
(SD ± 5.5 kg/m2)17. The physical status18 of patients was mild or ﬁt
Fig. 2. Trends in outcomes following primary total knee replacement (TKR) in England, UK, 2008e2016, by month. (A) Length of stay (LOS) at hospital; (B) change in self-reported
pain and function, measured using Oxford knee score (OKS) at baseline and 6 months after the surgery; (C) any complication in the following 6 months after primary TKR; (D) knee
revision in the following 5 years; enhanced recovery after surgery programme implemented in England from April 2009 to March 2011, ERAS.
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for 83% according to the American Society of Anesthesiologists (ASA
grade).
LOS
479,353 patients were used for the analysis of LOS (Fig. 1). LOS
decreased from 5.8 days (95% CI: 5.75.9) in April 2008 to 3.7 (95%
CI: 3.73.8) in December 2016 [Fig. 2(A)]. Prior to ERAS LOS was
already decreasing signiﬁcantly by 0.032% every month (95%
CI:0.035% to0.028%) (Table I). The rate of reduction inmean LOS
declined at a slower rate (0.016%, i.e., baseline trend e trend
change after ERAS) after the intervention period (April
2011December 2016).
Although older patients had a longer LOS, the secular trends in
decreasing LOS were seen across all age groups (e.g., 5.1 days (95%
CI: 4.95.4) to 3.3 days (95% CI: 3.13.4) in those age 18e59 and 7.7
days (95% CI: 7.28.2) to 5.4 days (95% CI: 5.15.8) in age 85)
(Fig. 3, Supplementary Table S1). Secular trends also decreased in
patients with and without pre-existing co-morbidity (Fig. 4). Cost
data were estimated for a total of 479,353 patients. The results for
mean inpatient bed day cost over time shows a similar trend to that
observed for LOS. Overall mean cost of the index hospital episode
decreased from £7607 (95% CI: £7511£7704) in April 2008 to
£5276 (95% CI: £5213£5339) in December 2016 (Fig. 5).
OKS change
We excluded 48% of patients with missing information for OKS
in the analysis of change in PROMs (Fig. 1). We found more missing
data for OKS change prior to ERAS (88.6%) than in the imple-
mentation period or after ERAS (43.0% and 45.0%, respectively)
(Supplementary Table S2). Supplementary Table S3 shows more
patients without data for OKS change than with data in the period
prior to ERAS (15.7% and 1.9%, respectively).
Over the study period therewas an improvement in OKS change
6 months after surgery of 15.1 points (95% CI: 14.116.2) in April
2008, to 17.1 points (95% CI: 16.218.1) in December 2016
[Fig. 2(B)]. The improvement in the secular trends was observed
across all age categories and patients with and without co-
morbidity (Figs. 6 and 7, Supplementary Table S4). For the sensi-
tivity analysis imputing OKS change we observed similar results
(Supplementary Figs. S2 and S3, Supplementary Tables S5 and S6).
The interrupted time-series model for OKS change shows that
prior to ERAS OKS change increased by 0.052% (95% CI: 0.044% to
0.148%) every month (Table I) and in the imputed dataset by 0.053%
(95% CI: 0.042%0.064%) (Supplementary Table S5). During ERAS
implementation (April 2009March 2011) the secular trend slowed
down by 0.009 and increased signiﬁcantly again after ERAS by
0.071.
Complication at 6-months
6884 (1.6%) patients had one or more complications 6 months
after TKR. The proportion of complications decreased from 4.1%
(95% CI: 3.54.8) to 1.7% (95% CI: 1.32.0) [Fig. 2(C)]. The inter-
rupted time-series model for complications at 6 months shows that
prior to ERAS complication proportion decreased by0.058% every
month (95% CI: 0.071% to 0.045%) (Table I). The period after the
ERAS intervention remained stable.
5-Year revision rates
3917 (2.2%) patients had a knee revision in the following 5 years
according to the NJR registry. We found 30 more 5-year revisions
using HES giving a total of 3947 (2.2%). Rates of 5-year knee revision
per 1000 implant year remained unchanged with a rate of 4.8 per
1000 implants years (95% CI: 3.96.0) at risk in April 2008 and 4.8
(95% CI: 3.9e5.9) in December 2011 [Fig. 2(D)].
Table I
Temporal trends in patients underwent planned primary total knee replacement (TKR) from April 2008 to December 2016. Full models with NeweyeWest standard errors
Parameter Coefﬁcient Lower 95% CI Upper 95% CI P-value
LOS
Intercept 5.871 5.852 5.890 <0.001
Monthly trend 0.032 0.035 0.028 <0.001
Level change ERAS0 0.158 0.106 0.210 <0.001
Trend change after ERAS0 0.002 0.002 0.006 0.395
Level change ERASend 0.091 0.171 0.012 0.025
Trend change after ERASend 0.016 0.013 0.018 <0.001
OKS 6 months e OKS baseline
Intercept 14.020 13.376 14.664 <0.001
Monthly trend 0.052 0.044 0.148 0.285
Level change ERAS0 0.261 0.286 0.808 0.346
Trend change after ERAS0 0.043 0.146 0.059 0.404
Level change ERASend 0.325 0.003 0.647 0.048
Trend change after ERASend 0.019 0.003 0.036 0.024
Complication by 6 months
Intercept 4.049 3.936 4.162 <0.001
Monthly trend 0.058 0.071 0.045 <0.001
Level change ERAS0 0.807 1.363 0.250 0.005
Trend change after ERAS0 0.003 0.044 0.039 0.899
Level change ERASend 0.314 0.074 0.702 0.112
Trend change after ERASend 0.058 0.021 0.095 0.002
Revision rates by 5 years
Intercept 4.833 4.597 5.068 <0.001
Monthly trend 0.014 0.011 0.039 0.255
Level change ERAS0 0.090 0.313 0.133 0.418
Trend change after ERAS0 0.031 0.058 0.003 0.031
Level change ERASend 0.095 0.323 0.132 0.402
Trend change after ERASend 0.040 0.021 0.060 <0.001
Total knee replacement, TKR; conﬁdence intervals, CI; length of stay at hospital, LOS; Oxford knee score, OKS; Enhanced Recovery Pathway, ERAS; start point of ERAS
intervention in April 2009, ERAS0; end point of ERAS intervention in March 2011, ERASend.
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The model for 5-year knee-revision rates shows a signiﬁcant
downward trend of 0.031 per 1000 implants years (95%
CI: 0.058 to 0.003) during ERAS implementation (April
2009eMarch 2011) (Table I). The trend changed direction by
increasing during the post-intervention period (April
2011eDecember 2016) in 0.040 per 1000 implants years (95% CI:
0.021e0.060).
Discussion
Prior to the introduction of ERAS LOS and inpatient bed-day cost
were declining. Although LOS and inpatient bed-day cost continued
to decrease after ERAS implementation, this was at half the rate of
decline. The absolute change in OKS was higher following ERAS
implementation, but although signiﬁcant, it did not reach clinical
signiﬁcance. There was no change in complications, while the 5-
year revision trend slightly increases after ERAS. LOS and OKS
trends were seen across all age groups, and in those with and
without co-morbidity. Reductions in LOS have been achieved
without adversely impacting on patient outcomes. However,
implementation of ERAS either slowed down or maintained pre-
existing secular trends.
We know from other UK studies that LOS has been in gradual
decline in the years prior to 2008, where Burn et al. found that in
1997 mean LOS for TKR was 18.89 days, and in 2008, before the
ERAS intervention, 7.49 days19. We expected to observe a steeper
trend in the decrease in LOS after the intervention period
(2009e2011). Although we did not a-priori know what pattern
would be expected prior to ERAS for the other outcomes, we hy-
pothesized that following the intervention, outcomes of patient
reported pain and function, complications, and revision surgery
should improve.
Our assumptions, for this “natural experiment” of the imple-
mentation of ERAS, were that this large scale intervention was
implemented homogenously across all England NHS trusts span-
ning this 2-year period. There was already an encouraging trend
towards reduction in LOS and improved outcomes that had begun
prior to the ofﬁcial ERAS programme. This is likely to reﬂect early
adoption of elements of ERAS methods in some Trusts, prior to the
start of the Department of Health led programme in 2009. Not all
hospitals had implemented ERAS at the end of the implementation
period (March 2011)11. The survey on the spread and adoption of
ERAS carried out close to the end of the implementation (February
2011) by the Department of Health reported full implementation in
81 consultant teams, while about 20 had partially implemented
ERAS, and about 30 still planned to implement ERAS. A limitation is
the variation in interpretation and adoption across centres because
what constitutes ERAS was not clearly established after the ex-
pected identiﬁcation of best practices in the ﬁrst year of the ERAS
programme20.
Fig. 3. Trends of length of stay (LOS) at hospital following primary TKR according to age categories in England, UK, 2008e2016, by month. Total knee replacement, TKR; enhanced
recovery after surgery programme implemented in England from April 2009 to March 2011, ERAS.
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Fig. 4. Trends of length of stay (LOS) at hospital following primary TKR by patients with/without comorbidities in England, UK, 2008e2016, by month. Total knee replacement, TKR;
enhanced recovery after surgery programme implemented in England from April 2009 to March 2011, ERAS.
Fig. 5. Trends of cost per bed day following primary TKR in England, UK, 2008e2016, by month. Total knee replacement, TKR; enhanced recovery after surgery programme
implemented in England from April 2009 to March 2011, ERAS.
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Dates of implementation of ERAS were different among hospi-
tals. How long that implementation could span or actually spanned
are not provided in the Department of Health guideline or in the
subsequent report11,20. Because of the complexity of the interven-
tion and stakeholders involved this could vary between hospitals.
Therefore, our quasi-experimental approach smoothed dissimilar-
ities in times used to adopt the ERAS intervention.
External inﬂuencing factors
Our results show trends in outcomes that has been achieved in
the context of an increasing strain on NHS funding and hospital
budgets. NHS funding growth is much slower than the historical
long term trend21. There are fewer hospital beds and wards have
been closed. For example, the average daily number of occupied
beds open overnight for trauma and orthopaedics for England be-
tween April and June 2010 was 10,015 while in October to
December 2016 was 877022. Conversely, the number of primary
knee replacements increased from 74,277 in 2008 to 98,147 in
201623 in England. It has been estimated that 118,666 TKRswill take
place by the year 203524. Further to this, the complexity of patients
has changed over time, with more patients with co-morbidities
now receiving surgery. Efﬁciencies need to be made to meet this
demandwithin existing or lower capacity. An important issue is the
high variation in services and practices across hospitals in England.
The Getting It Right First Time (GIRFT) programme aims to reduce
discrepancies between hospitals showing diversity in activity vol-
umes, implant choice, and guidelines follow-up25. The ﬁrst GIRFT
report was published in 2012, while the improving trends in out-
comes in our study are detected since 2008. Although our results of
a positive national trend are encouraging, there still remains sub-
stantial variation in outcomes between hospital trusts. In 2016,
mean LOS varied between a low of 2.2 days to a high of 5.6, and OKS
between 12.8 and 22.3 points. Hence although the national picture
has improved for patients as a whole, there is still work to be done
to reduce and understand unwarranted variations in outcome be-
tween individual hospitals.
Many studies supporting the implementation of ERAS pathways
have been placed in single institutions or rather small trials26. Thus,
they may not be generalizable to the wider population. Reductions
in LOS prior to the ofﬁcial implementation of ERAS may reﬂect a
commitment to improving the cost-effectiveness of this surgery
which represents an important expenditure for the NHS19,27,28.
Reduction in LOS has been reported in systematic reviews and
randomised clinical trials comparing patients following an ERAS
programme for colorectal and other planned surgeries against
those under conventional care6. There is variation in the type of
ERAS intervention for knee replacement that has been evaluated
among previous studies29e35 that preclude us to make general-
izations at a nationwide level. Additionally, these studies were
Fig. 6. Trends of OKS change following primary TKR according to age categories in England, UK, 2008e2016, by month. Oxford knee score, OKS; total knee replacement, TKR;
enhanced recovery after surgery programme implemented in England from April 2009 to March 2011, ERAS.
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limited to only one hospital or trust. Moreover, they were focused
on the comparison of the intervention with traditional manage-
ment. Our study investigates whether the ERAS pathway has been
successfully implemented comparing with a previous period
without ERAS, as has been done in other studies30e32, but also, and
for ﬁrst time, comparing with the post-intervention period.
The decreasing trend in LOS over time was also reﬂected in the
change in estimated average inpatient bed day cost. We found that
the majority of episodes in the data had a LOS less than the trim
point for the relevant cost HRG. This meant that (assigning the
same unit cost to all patients with the same HRG who had a LOS
below the trim point) the reduction in LOS within the trim point
would not be reﬂected by a change in the estimated average
episode costs. We therefore estimated the true reduction in NHS
expenditure by estimating a cost per bed day reﬂecting the LOS for
each patient.
OKS change scores increased across the study period. However,
the change of ~2e3 points using complete and imputed cases does
not reaching the clinically meaningful difference of 5 points sug-
gested within the literature36. A review on ERAS in total hip
replacement shows that better improvement in pain and function
scores could be related to making patients active participants in
their recovery and to help them to manage their expectations28. A
Cochrane review on preoperative education for hip or knee
replacement did not ﬁnd additional beneﬁts over usual care37.
However, non-signiﬁcant reduction of pain and better function
were reported to be associated with preoperative education.
The 6-month complications were decreasing until the imple-
mentation took place. Subsequently, the trend remained steady
during the ERAS period and slightly increased following the
intervention. Potentially, discharging patients too soon after sur-
gery could increase complications. However, a meta-analysis in
colorectal surgery on several ERAS programmes did not ﬁnd ev-
idence of an increased risk of surgical complications38, and found
that cardiovascular, pulmonary, and infectious medical compli-
cations decreased. Patients with diabetes undergoing hip and
knee replacement under ERAS protocols reduce the additional risk
for complications otherwise associated with operating patients
with diabetes39. A limitation is that manipulation under anaes-
thesia was not considered among the list of 6-month complica-
tions. Werner et al. found 4.24% requiring manipulation under
anaesthesia by 6 months in a large cohort of patients undergoing
TKR (n ¼ 141,016). 4.8% of them had a revision within the
following 7 years40.
5-year revision rates diminished across the study. It has been an
important effort to reduce revision rates because the procedure is
more complicated to perform41. Surveillance of knee replacement
revisions, using joint registries, have long been themainmeasure of
primary surgical success/failure until PROMs were also used to
assess outcomes42. Revision rates could have declined as a conse-
quence of patient selection for primary surgery43.
To inform the list of important outcomes for this study, we
conducted a forum with the University of Bristol's Musculoskeletal
Research Unit's patient involvement group. Mortality was ranked
low by the group in respect of its importance to them, and hence
has not been included and remains a limitation of the analysis. We
did not included BMI as a potential modiﬁer for trends in LOS and
OKS. A slightly higher proportion of obese patients (35 kg/m2)
between 2008 and 2016 (21.4% and 25.3%, respectively) might in-
ﬂuence trends for LOS and OKS, respectively.
Fig. 7. Trends of OKS change following primary TKR by patients with/without comorbidities in England, UK, 2008e2016, by month. Oxford knee score, OKS; total knee replacement,
TKR; enhanced recovery after surgery programme implemented in England from April 2009 to March 2011, ERAS.
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Conclusion
Our study shows that trends of improved outcomes of planned
TKR slowed down after ERAS. LOS, OKS, complications and re-
visions are currently better than 10 years ago. LOS has declined
substantially over the study period, consistent across all age groups
and in people with and without co-morbidity. Nevertheless, de-
clines in LOS were half the initial decline following ERAS imple-
mentation. Reductions in LOS have been achieved without
adversely impacting on patient outcomes. Patient reported out-
comes in respect of pain and function have improved, but did not
reach clinical signiﬁcance. Complication rates remain stable and
revision rates decline less than before ERAS implementation. These
trends in outcomes have been achieved in the context of reductions
in the numbers of available beds/wards/operating theatres, with
increasing absolute numbers of patients undergoing TKR year on
year and sicker patients over the study time.
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Appendix 1. Cost methods
Objective
We aimed to estimate the trend in National Health Service
(NHS) expenditure over time, reﬂecting the change in length of stay
(LOS) observed.
Grouper and reference cost methods
Using Hospital Episode Statistics (HES) data for the same group
of patients as for LOS (i.e., excluding those with LOS above 15 days),
we generated healthcare resource use group (HRG) classiﬁcations
for the index episode for each patient using the 2015/16 NHS
reference costs grouper [1], which were subsequently used to es-
timate inpatient costs per patient using NHS reference costs from
2015/16 [2].
A reduction in LOS within the trim point is therefore not re-
ﬂected in the cost of the episode, despite there being a true
reduction in NHS costs. In order to estimate the mean change in
NHS expenditure we therefore estimated an adjusted average bed
day cost.
Estimating the adjusted average bed day cost
For each HRG we estimated the average cost per bed day
(deﬁned as any part of a day spent in hospital) by dividing the total
cost of the index episodes for that HRG by the total number of bed
days for that HRG. This generated a single average bed day cost per
HRG.
For each patient we estimated the adjusted episode cost by
multiplying their LOS (bed days) by the average bed day cost for the
HRG that they had been assigned by the NHS reference costs
grouper [1]. Therefore, instead of assigning the same unit cost to all
patients with the same HRG who had a LOS below the trim point,
the adjusted cost differed according to a patient's LOS, even if that
LOS was below the trim point for the HRG. Using this method we
were able to estimate the average difference in true NHS expen-
diture as a result of the reduction in LOS over time even when the
LOS was below the trim point.
The 2015/16 grouper and reference costs [1,2] were used to es-
timate costs for all patients in all years, as there are differences in
the methodologies used for HRG classiﬁcation in different cost
years [3]. This prevents a like-for-like comparison between years if
different groupers and/or costs are used.
Costs were estimated for a total of 517,798 patients.
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Appendix 2. Codes deﬁned in the International Statistical
Classiﬁcation of Diseases and Related Health Problems 10th
Revision (ICD-10) that we used to identify complications in
the Hospital Episode Statistics (HES) registry
Stroke
I60.X, “Subarachnoid haemorrhage”; I61.0, “Intracerebral hae-
morrhage in hemisphere, subcortical”; I61.1, “Intracerebral hae-
morrhage in hemisphere, cortical”; I61.2, “Intracerebral
haemorrhage in hemisphere, unspeciﬁed”; I61.3, “Intracerebral
haemorrhage in brain stem”; I61.4, “Intracerebral haemorrhage in
cerebellum”; I61.5, “Intracerebral haemorrhage, intraventricular”;
I61.6, “Intracerebral haemorrhage, multiple localized”; I61.8, “Other
intracerebral haemorrhage”; I61.9, “Intracerebral haemorrhage,
unspeciﬁed”; I63.0, “Cerebral infarction due to thrombosis of pre-
cerebral arteries”; I63.1, “Cerebral infarction due to embolism of
precerebral arteries”; I63.2, “Cerebral infarction due to unspeciﬁed
occlusion or stenosis of precerebral arteries”; I63.3, “Cerebral
infarction due to thrombosis of cerebral arteries”; I63.4, “Cerebral
infarction due to embolism of cerebral arteries”; I63.5, “Cerebral
infarction due to unspeciﬁed occlusion or stenosis of cerebral ar-
teries”; I63.6, “Cerebral infarction due to cerebral venous throm-
bosis, nonpyogenic”; I63.8, “Other cerebral infarction”; I63.9,
“Cerebral infarction, unspeciﬁed”; and I64.X, “Stroke, not speciﬁed
as haemorrhage or infarction”.
Respiratory infection
J12.X, “Viral pneumonia, not elsewhere classiﬁed: broncho-
pneumonia due to viruses other than inﬂuenza viruses”; J13,
“Pneumonia due to Streptococcus pneumoniae”; J14, “Pneumonia
due to Haemophilus inﬂuenzae”; J15.X, “Bacterial pneumonia, not
elsewhere classiﬁed: bronchopneumonia due to bacteria other than
S. pneumoniae and H. inﬂuenzae”; J18.0, “Bronchopneumonia, un-
speciﬁed. Excluding bronchiolitis”; J18.1, “Lobar pneumonia, un-
speciﬁed”; J18.2, “Hypostatic pneumonia, unspeciﬁed”; J18.8,
“Other pneumonia, organism unspeciﬁed”; J18.9, “Pneumonia,
unspeciﬁed”; J22, “Unspeciﬁed acute lower respiratory infection”;
J44.0, “Chronic obstructive pulmonary disease with acute lower
respiratory infection. Excluding with inﬂuenza”; J44.1, “Chronic
obstructive pulmonary disease with acute exacerbation, unspeci-
ﬁed”; J69.0, “Pneumonitis due to food and vomit. Excluding Men-
delson syndrome”; J69.1, “Pneumonitis due to oils and essences”;
J69.8, “Pneumonitis due to other solids and liquids. Pneumonitis
due to aspiration of blood”; and J85.1, “Abscess of lung with
pneumonia. Excluding with pneumonia due to speciﬁed organism”.
Acute myocardial infarction
I21.0, “Acute transmural myocardial infarction of anterior wall”;
I21.1, “Acute transmural myocardial infarction of inferior wall”;
I21.2, “Acute transmural myocardial infarction of other sites”; I21.3,
“Acute transmural myocardial infarction of unspeciﬁed site”; I21.4,
“Acute subendocardial myocardial infarction”; and I21.9, “Acute
myocardial infarction, unspeciﬁed”.
Pulmonary embolism/deep vein thrombosis
I80.1, “Phlebitis and thrombophlebitis of superﬁcial vessels of
lower extremities”; I80.1, “Phlebitis and thrombophlebitis of
femoral vein”; I80.3, “Phlebitis and thrombophlebitis of other deep
vessels of lower extremities”; I26.0, “Pulmonary embolism with
mention of acute cor pulmonale”; and I26.9, “Pulmonary embolism
without mention of acute cor pulmonale”.
Urinary tract infection
N30.0, “Acute cystitis. Excluding irradiation cystitis and trig-
onitis”; and N39.0, “Urinary tract infection, site not speciﬁed”.
Wound disruption
T81.3, “Disruption of operation wound, not elsewhere
classiﬁed”.
Surgical site infection
T81.4, “Infection following a procedure, not elsewhere
classiﬁed”.
Fracture after implant
M96.6, “Fracture of bone following insertion of orthopaedic
implant, joint prosthesis, or bone plate. Excluding complication of
internal orthopaedic devices, implants or grafts”.
Complication of prosthesis
T84.0, “Mechanical complication of internal joint prosthesis”.
Neurovascular injury
T81.2, “Accidental puncture and laceration during a procedure,
not elsewhere classiﬁed. Accidental perforation of: blood vessel,
nerve or organ by: catheter, endoscope, instrument or probe during
a procedure”.
Acute renal failure
N17.0, “Acute renal failure with tubular necrosis”; N17.1, “Acute
renal failure with acute cortical necrosis”; N17.2, “Acute renal fail-
ure with medullary necrosis”; N17.8, “Other acute renal failure”;
and N17.9, “Acute renal failure, unspeciﬁed”.
Appendix 3. Operative procedure codes (OPCS 4.8) that we
used to identify blood-transfusion complication in the
Hospital Episode Statistics (HES) registry
X33.2, “Intravenous blood transfusion of packed cells”; X33.3,
“Intravenous blood transfusion of platelets”; X33.8, “Other speci-
ﬁed other blood transfusion”; X33.9, “Unspeciﬁed other blood
transfusion”; X33.1, “Intra-arterial blood transfusion”; X33.7,
“Autologous transfusion of red blood cells”; X34.1, “Transfusion of
coagulation factor”; X34.2, “Transfusion of plasma not elsewhere
classiﬁed”; X34.3, “Transfusion of serum not elsewhere classiﬁed”;
and X34.4, “Transfusion of blood expander”.
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Appendix 4. Operative procedure codes (OPCS 4.8) that we
used to identify knee revision in the Hospital Episode
Statistics (HES) registry
Algorithm
One code from procedure type 1 or a combination of one code
from procedure type 2 and site for revision were used to identify
knee revision. Combination of codes from procedures type 3 and
type 1 or procedure type 3, type 2 and site of surgery identiﬁed
knee revision after a primary knee unicompartmental replacement
(UKR).
Code Procedure
Procedure type 1
W40.0 Conversion from previous cemented total prosthetic replacement of knee joint
W40.2 Conversion to total prosthetic replacement of knee joint using cement
W40.3 Revision of total prosthetic replacement of knee joint using cement
W40.4 Revision of one component of total prosthetic replacement of knee joint using cement
W41.0 Conversion from previous uncemented total prosthetic replacement of knee joint
W41.2 Conversion to total prosthetic replacement of knee joint not using cement
W41.3 Revision of total prosthetic replacement of knee joint not using cement
W41.4 Revision of one component of total prosthetic replacement of knee joint not using cement
W42.0 Conversion from previous total prosthetic replacement of knee joint not elsewhere speciﬁed (NEC)
W42.2 Conversion to total prosthetic replacement of knee joint NEC
W42.3 Revision of total prosthetic replacement of knee joint NEC
W42.4 Attention to total prosthetic replacement of knee joint NEC
W42.5 Revision of one component of total prosthetic replacement of knee joint NEC
W42.6 Arthrolysis of total prosthetic replacement of knee joint
W58.0 Conversion from previous resurfacing arthroplasty of joint
O18.0 Conversion from previous hybrid prosthetic replacement of knee joint using cement
O18.2 Conversion to hybrid prosthetic replacement of knee joint using cement
O18.3 Revision of hybrid prosthetic replacement of knee joint using cement
O18.4 Attention to hybrid prosthetic replacement of knee joint using cement
Procedure type 2
W52.0 Conversion from previous cemented prosthetic replacement of articulation of bone NEC
W52.2 Conversion to prosthetic replacement of articulation of bone using cement NEC
W52.3 Revision of prosthetic replacement of articulation of bone using cement NEC
W53.0 Conversion from previous uncemented prosthetic replacement of articulation of bone NEC
W53.2 Conversion to prosthetic replacement of articulation of bone not using cement NEC
W53.3 Revision of prosthetic replacement of articulation of bone not using cement NEC
W54.0 Conversion from previous prosthetic replacement of articulation of bone NEC
W54.2 Conversion to prosthetic replacement of articulation of bone NEC
W54.3 Revision of prosthetic replacement of articulation of bone NEC
W54.4 Attention to prosthetic replacement of articulation of bone NEC
W55.3 Conversion to prosthetic interposition arthroplasty of joint
W56.4 Conversion to interposition arthroplasty of joint NEC
W57.4 Conversion to excision arthroplasty of joint
W60.3 Conversion to arthrodesis and extra-articular bone graft NEC
W61.3 Conversion to arthrodesis and articular bone graft NEC
W64.1 Conversion to arthrodesis and internal ﬁxation NEC
W64.2 Conversion to arthrodesis and external ﬁxation NEC
Site for revision
Z76.5 Lower end of femur NEC
Z77.4 Upper end of tibia NEC
Z78.7 Patella
Z84.4 Patellofemoral joint
Z84.5 Tibiofemoral joint
Z84.6 Knee joint
Procedure type 3
W40.1 Primary total prosthetic replacement of knee joint using cement
W40.8 Other speciﬁed total prosthetic replacement of knee joint using cement
W40.9 Unspeciﬁed total prosthetic replacement of knee joint using cement
W41.1 Primary total prosthetic replacement of knee joint not using cement
W41.8 Other speciﬁed total prosthetic replacement of knee joint not using cement
W41.9 Unspeciﬁed total prosthetic replacement of knee joint not using cement
W42.1 Primary total prosthetic replacement of knee joint NEC
W42.8 Other speciﬁed other total prosthetic replacement of knee joint
W42.9 Unspeciﬁed other total prosthetic replacement of knee joint
O18.1 Primary hybrid prosthetic replacement of knee joint using cement
O18.8 Other speciﬁed hybrid prosthetic replacement of knee joint using cement
O18.9 Unspeciﬁed hybrid prosthetic replacement of knee joint using cement
C. Garriga et al. / Osteoarthritis and Cartilage 27 (2019) 1280e1293 1291
Appendix 5. Codes deﬁned in the International Statistical
Classiﬁcation of Diseases and Related Health Problems 10th
Revision (ICD-10) that we used to identify comorbidities in the
Hospital Episode Statistics (HES) registry
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